Treatment of metastatic neuroendocrine carcinomas based on WHO classification

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4463-4469

  Artale, Salvatore ^a   Giannetta, Laura ^a   Cerea, Giulio ^a   Pedrazzoli, Paolo ^a   Schiavetto, Ilaria ^a   Napolitano, Marcello ^a   Veronese, Silvio ^a   Bramerio, Emanuela ^a   Gambacorta, Marcello ^a   Vanzulli, Angelo ^a   Pisconti, Salvatore ^b   Pugliese, Raffaele ^a   Siena, Salvatore ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Ausl Taranto/01   (Italy)

Author keywords

Biotherapy; Chemotherapy; Neuroendocrine carcinomas

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATININE; FLUOROURACIL; FOLINIC ACID; OCTREOTIDE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CARCINOID SYNDROME; CHEMOTHERAPY INDUCED EMESIS; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; DIARRHEA; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LOW DRUG DOSE; MALE; METASTASIS; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PRURITUS; SURVIVAL RATE; SUSTAINED DRUG RELEASE; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NEUROENDOCRINE; CHROMOGRANINS; CISPLATIN; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; HYDROXYINDOLEACETIC ACID; INTERFERON ALFA-2B; LEUCOVORIN; MALE; MIDDLE AGED; OCTREOTIDE; PHOSPHOPYRUVATE HYDRATASE; PROSPECTIVE STUDIES;

EID: 28444436906     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Solcia E, Klöppel G and Sobhin LH: Histological Typing of Endocrine Tumours. Springer-Verlag: New York, 2000.
2. Dogliotti L, Tampellini M, Stivanello M, Gorzegno G and Fabiani L: The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Ann Oncol 12 Suppl 2: S105-109, 2001.
3. Wiedenmann B and Pape UF: From basic to clinical research in gastroenteropancreatic neuroendocrine tumor disease - the clinician-scientist perspective. Neuroendocrinology 80 Suppl 1: 94-98, 2004.
4. Ruszniewski P and Malka D: Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 62 Suppl 1: 79-83, 2000.
5. Oberg K: Established clinical use of octreotide and lanreotide in oncology. Chemotherapy 47 Suppl 2: 40-53, 2001.
6. Eriksson B and Oberg K: Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 10 Suppl 2: S31-38, 1999.
7. Scherubl H, Wiedenmann B, Riecken EO, Thomas F, Bohme E and Rath U: Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. Eur J Cancer 30A: 1590-1591, 1994.
8. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Hammel P and Rougier P: The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 95: 3276-3281, 2000.
9. Kolby L, Persson G, Franzen S and Ahren B: Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90: 687-693, 2003.
10. Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1: 727-740, 1983.
11. Engstrom PF, Lavin PT, Moertel CG, Folsch E and Douglass HO Jr: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2: 1255-1259, 1984.
12. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET and Eriksson BK: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92: 1101-1107, 2001.
13. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G and Solcia E: Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 429: 323-333, 1996.
14. Rorstad O: Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 89: 151-160, 2005.
15. Oberg K: Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 14: 38-45, 2002.
16. Oberg, K: Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 5: 110-120, 1993.
17. Pelley RJ and Bukowski RM: Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors. Curr Opin Oncol 11: 32-37, 1999.
18. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
20. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
21. Oberg K: Management of neuroendocrine tumours. Ann Oncol 15 Suppl 4: iv293-298, 2004.
22. Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder, W, Riecken EO and Wiedenmann B: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21: 2689-2696, 2003.
23. Bajetta E, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E and Bombardieri E: Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. Ann Oncol 13: 614-621, 2002.
24. Ollivier S, Fonck M, Becouarn Y and Brunet R: Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial. Am J Clin Oncol 21: 237-240, 1998.
25. Fjallskog ML, Sundin A, Westlin JE, Oberg K, Janson ET and Eriksson B: Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol 19: 35-42, 2002.
26. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M and Rougier P: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81: 1351-1355, 1999.
27. Moertel CG, Lefkopoulo M, Lipsit S, Hahn RG and Klaassen D: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326: 519-523, 1992.